

Dimitrios Mavroudis

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/5441231/publications.pdf>

Version: 2024-02-01

66
papers

2,169
citations

471371

17
h-index

233338

45
g-index

66
all docs

66
docs citations

66
times ranked

3146
citing authors

#	ARTICLE	IF	CITATIONS
1	Clinical validity of circulating tumour cells in patients with metastatic breast cancer: a pooled analysis of individual patient data. <i>Lancet Oncology</i> , The, 2014, 15, 406-414.	5.1	703
2	Epithelial to mesenchymal transition markers expressed in circulating tumour cells of early and metastatic breast cancer patients. <i>Breast Cancer Research</i> , 2011, 13, R59.	2.2	327
3	The clinical use of circulating tumor cells (CTCs) enumeration for staging of metastatic breast cancer (MBC): International expert consensus paper. <i>Critical Reviews in Oncology/Hematology</i> , 2019, 134, 39-45.	2.0	200
4	Circulating Tumor Cells with Stemness and Epithelial-to-Mesenchymal Transition Features Are Chemoresistant and Predictive of Poor Outcome in Metastatic Breast Cancer. <i>Molecular Cancer Therapeutics</i> , 2019, 18, 437-447.	1.9	133
5	Co-expression of putative stemness and epithelial-to-mesenchymal transition markers on single circulating tumour cells from patients with early and metastatic breast cancer. <i>BMC Cancer</i> , 2014, 14, 651.	1.1	97
6	Circulating microRNAs in the early prediction of disease recurrence in primary breast cancer. <i>Breast Cancer Research</i> , 2018, 20, 72.	2.2	69
7	Clinical Relevance of Immune Checkpoints on Circulating Tumor Cells in Breast Cancer. <i>Cancers</i> , 2020, 12, 376.	1.7	52
8	Efficacy of Lapatinib in Therapy-Resistant HER2-Positive Circulating Tumor Cells in Metastatic Breast Cancer. <i>PLoS ONE</i> , 2015, 10, e0123683.	1.1	49
9	A Comparison of Three Methods for the Detection of Circulating Tumor Cells in Patients with Early and Metastatic Breast Cancer. <i>Cellular Physiology and Biochemistry</i> , 2017, 44, 594-606.	1.1	38
10	Circulating miRNAs as a marker of metastatic disease and prognostic factor in metastatic breast cancer. <i>Oncotarget</i> , 2019, 10, 966-981.	0.8	38
11	Targeting angiogenesis in small cell lung cancer. <i>Translational Lung Cancer Research</i> , 2016, 5, 389-400.	1.3	37
12	Optimization of the Enrichment of Circulating Tumor Cells for Downstream Phenotypic Analysis in Patients with Non-Small Cell Lung Cancer Treated with Anti-PD-1 Immunotherapy. <i>Cancers</i> , 2020, 12, 1556.	1.7	27
13	Expression of truncated human epidermal growth factor receptor 2 on circulating tumor cells of breast cancer patients. <i>Breast Cancer Research</i> , 2015, 17, 113.	2.2	24
14	Serial Analysis of Circulating Tumor Cells in Metastatic Breast Cancer Receiving First-Line Chemotherapy. <i>Journal of the National Cancer Institute</i> , 2021, 113, 443-452.	3.0	22
15	Cancer cachexia syndrome and clinical outcome in patients with metastatic non-small cell lung cancer treated with PD-1/PD-L1 inhibitors: results from a prospective, observational study. <i>Translational Lung Cancer Research</i> , 2021, 10, 3538-3549.	1.3	21
16	Immunotherapy in Metastatic Colorectal Cancer: Could the Latest Developments Hold the Key to Improving Patient Survival?. <i>Cancers</i> , 2020, 12, 889.	1.7	20
17	Prediction of outcome in patients with non-small cell lung cancer treated with second line PD-1/PDL-1 inhibitors based on clinical parameters: Results from a prospective, single institution study. <i>PLoS ONE</i> , 2021, 16, e0252537.	1.1	20
18	The Prognostic Value of the Detection of Microbial Translocation in the Blood of Colorectal Cancer Patients. <i>Cancers</i> , 2020, 12, 1058.	1.7	19

#	ARTICLE	IF	CITATIONS
19	Regulatory T-cell Transcriptomic Reprogramming Characterizes Adverse Events by Checkpoint Inhibitors in Solid Tumors. <i>Cancer Immunology Research</i> , 2021, 9, 726-734.	1.6	19
20	Detection of KRAS G12/G13 Mutations in Cell Free-DNA by Droplet Digital PCR, Offers Prognostic Information for Patients with Advanced Non-Small Cell Lung Cancer. <i>Cells</i> , 2020, 9, 2514.	1.8	18
21	International real-world study of DLL3 expression in patients with small cell lung cancer. <i>Lung Cancer</i> , 2020, 147, 237-243.	0.9	17
22	The Role of Vitamin D Receptor Gene Polymorphisms in Colorectal Cancer Risk. <i>Cancers</i> , 2020, 12, 1379.	1.7	17
23	Correlation of PKM2 and CD44 Protein Expression with Poor Prognosis in Platinum-Treated Epithelial Ovarian Cancer: A Retrospective Study. <i>Cancers</i> , 2020, 12, 1013.	1.7	17
24	Circulating MicroRNAs Regulating DNA Damage Response and Responsiveness to Cisplatin in the Prognosis of Patients with Non-Small Cell Lung Cancer Treated with First-Line Platinum Chemotherapy. <i>Cancers</i> , 2020, 12, 1282.	1.7	17
25	PKM2 Expression as Biomarker for Resistance to Oxaliplatin-Based Chemotherapy in Colorectal Cancer. <i>Cancers</i> , 2020, 12, 2058.	1.7	14
26	MicroRNAs Regulating Tumor Immune Response in the Prediction of the Outcome in Patients With Breast Cancer. <i>Frontiers in Molecular Biosciences</i> , 2021, 8, 668534.	1.6	14
27	Epithelial/Mesenchymal Characteristics and PD-L1 Co-Expression in CTCs of Metastatic Breast Cancer Patients Treated with Eribulin: Correlation with Clinical Outcome. <i>Cancers</i> , 2020, 12, 3735.	1.7	11
28	Assessment of the Efficacy and Clinical Utility of Different Circulating Tumor Cell (CTC) Detection Assays in Patients with Chemotherapy-Naïve Advanced or Metastatic Non-Small Cell Lung Cancer (NSCLC). <i>International Journal of Molecular Sciences</i> , 2021, 22, 925.	1.8	11
29	Epithelial-to-mesenchymal Transition Heterogeneity of Circulating Tumor Cells and Their Correlation With MDSCs and Tregs in HER2-negative Metastatic Breast Cancer Patients. <i>Anticancer Research</i> , 2021, 41, 661-670.	0.5	11
30	Arterial Stents for Access and Protection of the Parotid and Submandibular Ducts During Sialoendoscopy. <i>Journal of Oral and Maxillofacial Surgery</i> , 2007, 65, 1865-1868.	0.5	10
31	Serum IGF-1, IGFBP-3 levels and circulating tumor cells (CTCs) in early breast cancer patients. <i>Growth Hormone and IGF Research</i> , 2017, 33, 28-34.	0.5	10
32	A Prognostic Role for Circulating microRNAs Involved in Macrophage Polarization in Advanced Non-Small Cell Lung Cancer. <i>Cells</i> , 2021, 10, 1988.	1.8	9
33	Utilization of Systemic Chemotherapy in Advanced Urothelial Cancer: A Retrospective Collaborative Study by the Hellenic Genitourinary Cancer Group (HGUCG). <i>Clinical Genitourinary Cancer</i> , 2016, 14, e153-e159.	0.9	8
34	Detection of KRAS Exon 2 Mutations in Circulating Tumor Cells Isolated by the ISET System from Patients with RAS Wild Type Metastatic Colorectal Cancer. <i>Translational Oncology</i> , 2017, 10, 693-698.	1.7	7
35	The Effect of Long-Term Atorvastatin Therapy on Carotid Intima-Media Thickness of Children With Dyslipidemia. <i>Angiology</i> , 2021, 72, 322-331.	0.8	7
36	TLR4 and pSTAT3 Expression on Circulating Tumor Cells (CTCs) and Immune Cells in the Peripheral Blood of Breast Cancer Patients: Prognostic Implications. <i>Cancers</i> , 2022, 14, 1053.	1.7	7

#	ARTICLE	IF	CITATIONS
37	Evaluation of the Role of Circulating Tumor Cells and Microsatellite Instability Status in Predicting Outcome of Advanced CRC Patients. <i>Journal of Personalized Medicine</i> , 2020, 10, 235.	1.1	6
38	A phase II study of nab-paclitaxel and carboplatin chemotherapy plus necitumumab in the first-line treatment of patients with stage IV squamous non-small cell lung cancer. <i>Lung Cancer</i> , 2019, 136, 52-56.	0.9	5
39	Cardiovascular Risk Factors and Subclinical Atherosclerosis in Greek Adolescents with Polycystic Ovary Syndrome: Its Relationship with Body Mass Index. <i>Children</i> , 2022, 9, 4.	0.6	5
40	Modeling the Prognostic Impact of Circulating Tumor Cells Enumeration in Metastatic Breast Cancer for Clinical Trial Design Simulation. <i>Oncologist</i> , 2022, 27, e561-e570.	1.9	5
41	Resectable Colorectal Cancer: Current Perceptions on the Correlation of Recurrence Risk, Microbiota and Detection of Genetic Mutations in Liquid Biopsies. <i>Cancers</i> , 2021, 13, 3522.	1.7	4
42	Intramenigeoma metastasis: A case-based literature review. <i>Journal of Clinical Neuroscience</i> , 2021, 93, 168-173.	0.8	4
43	Detection of Circulating Tumor Cells and Microbial DNA Fragments in Stage III Colorectal Cancer Patients under Three versus Six Months of Adjuvant Treatment. <i>Cancers</i> , 2021, 13, 3552.	1.7	3
44	The impact of circulating tumor cells (CTCs) detection in metastatic breast cancer (MBC): Implications of indolent stage IV disease (Stage IV indolent).. <i>Journal of Clinical Oncology</i> , 2018, 36, 1019-1019.	0.8	3
45	Circulating miRNAs as Potential Biomarkers in Prostate Cancer Patients Undergoing Radiotherapy. <i>Cancer Management and Research</i> , 2021, Volume 13, 8257-8271.	0.9	3
46	Single-Cell RNA Sequencing Uncovers Heterogeneous Circulating Tumor Cell Subsets in Breast Cancer. <i>Cancers</i> , 2022, 14, 1314.	1.7	3
47	MicroRNAs Regulating Tumor and Immune Cell Interactions in the Prediction of Relapse in Early Stage Breast Cancer. <i>Biomedicines</i> , 2021, 9, 421.	1.4	2
48	Cancer cachexia, sarcopenia and hand-GRIP strength (HGS) in the prediction of outcome in patients with metastatic non-small cell lung cancer (NSCLC) treated with immune checkpoint inhibitors (ICIs): A prospective, observational study.. <i>Journal of Clinical Oncology</i> , 2019, 37, 9099-9099.	0.8	2
49	Messenger-RNA Expression of Five Gemcitabine Sensitivity-related Genes Predicting Outcome in Advanced-stage Non-small Cell Lung Cancer. <i>Anticancer Research</i> , 2020, 40, 901-913.	0.5	1
50	Detection of circulating tumor cells in the peripheral blood of patients with small cell lung cancer (SCLC) using both the CellSearch platform and immunofluorescence: Correlation with clinicopathological features.. <i>Journal of Clinical Oncology</i> , 2015, 33, 7573-7573.	0.8	1
51	Three versus six months adjuvant FOLFOX or CAPOX for high risk stage II and stage III colon cancer patients: The efficacy results of Hellenic Oncology Research Group (HORC) participation to the International Duration Evaluation of Adjuvant chemotherapy (IDEA) project.. <i>Journal of Clinical Oncology</i> , 2019, 37, 3500-3500.	0.8	1
52	Real-World Data on Treatment Management and Outcomes of Patients with Newly Diagnosed Advanced Epithelial Ovarian Cancer in Greece (The EpOCa Study). <i>Current Oncology</i> , 2021, 28, 5266-5277.	0.9	1
53	A multicenter, randomized phase II study of sequential vinorelbine (V)/cisplatin (C)/bevacizumab (B) followed by docetaxel (D)/gemcitabine (G)/B versus D/C/B as a first-line therapy for advanced or metastatic nonsquamous non-small cell lung cancer (NSCLC).. <i>Journal of Clinical Oncology</i> , 2012, 30, e18105-e18105.	0.8	0
54	A pilot feasibility study to evaluate the efficacy of lapatinib in eliminating HER2-positive tumor cells circulating in peripheral blood of women with metastatic breast cancer.. <i>Journal of Clinical Oncology</i> , 2013, 31, e22105-e22105.	0.8	0

#	ARTICLE	IF	CITATIONS
55	Predictive value of BRCA1, ERCC1, ATP7B, PKM2, TOPO-I, TOPO-ii, TOPO-iib, and c-MYC genes in patients with small cell lung cancer (SCLC) who received first-line therapy with cisplatin and etoposide.. Journal of Clinical Oncology, 2013, 31, 7594-7594.	0.8	0
56	Peripheral immunosuppressive cell levels as predictive marker for the clinical outcome in stage IV colorectal carcinoma.. Journal of Clinical Oncology, 2013, 31, e14639-e14639.	0.8	0
57	A multicenter phase I-II trial of weekly paclitaxel and carboplatin plus bevacizumab in women with triple-negative metastatic breast cancer.. Journal of Clinical Oncology, 2013, 31, 1045-1045.	0.8	0
58	Effect of exemestane plus everolimus on CTC counts and Ki-67 expression on CTCs in patients with advanced hormone receptor-positive, HER2-negative breast cancer.. Journal of Clinical Oncology, 2014, 32, 11042-11042.	0.8	0
59	Patterns of practice in the management of advanced urothelial cancer (UC) in Greece: A retrospective analysis by the hellenic GU Cancer Group (HGUCG).. Journal of Clinical Oncology, 2014, 32, e15514-e15514.	0.8	0
60	PKM2 and CD44 tumoral expression to predict the effectiveness of front-line paclitaxel and carboplatin chemotherapy in epithelial ovarian cancer.. Journal of Clinical Oncology, 2015, 33, e16564-e16564.	0.8	0
61	Association of Ki-67 expression in CTCs with disease relapse in patients with early breast cancer (BC) and affect by the administration of adjuvant chemotherapy.. Journal of Clinical Oncology, 2016, 34, e23243-e23243.	0.8	0
62	Next generation sequencing to identify actionable mutations in EGFR-wild type and KRAS mutant non-small cell lung cancer patients ed by the administration of adjuvant chemotherapy.. Journal of Clinical Oncology, 2016, 34, e20630-e20630.	0.8	0
63	Prognostic value of circulating tumor cells in non-small cell lung cancer.. Journal of Clinical Oncology, 2017, 35, e20520-e20520.	0.8	0
64	Circulating microRNAs (miRNAs) as predictors of relapse in early breast cancer (BC).. Journal of Clinical Oncology, 2017, 35, e23030-e23030.	0.8	0
65	Detection of microbial DNA in the blood of colorectal cancer patients for the diagnosis of microbial translocation.. Journal of Clinical Oncology, 2020, 38, 171-171.	0.8	0
66	Microbial translocation, toll-like and vitamin D receptor polymorphisms in blood and risk of recurrence in stage III colorectal cancer.. Journal of Clinical Oncology, 2022, 40, 3531-3531.	0.8	0